RecruitingAnterior Cruciate Ligament Reconstruction
The Effects of Tranexamic Acid on Joint Inflammation and Cartilage Health in Anterior Cruciate Ligament Injured Patients
Eligible age
18–30 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
Patients who tear their ACL are at high risk for developing arthritis (post-traumatic osteoarthritis-PTOA) just 10 years later. Joint bleeding and inflammation contribute to deterioration of joint health. This study will determine whether treatment with Tranexamic Acid (TXA), an FDA approved medication that reduces bleeding right after ACL injury and reconstructive surgery reduces inflammation and improves joint health as a new strategy to prevent or delay the onset of PTOA.
Sponsor: Stanford University
You may qualify if…
- ✓ age 18-30 years
- ✓ within 4 days of unilateral ACL injury
- ✓ presence of effusion/hemarthrosis.
You may not qualify if…
- ✕ inflammatory arthritis, radiographic osteoarthritis (K-L Grade 2 or higher), gout/ pseudogout
- ✕ systemic or acute illness requiring medications
- ✕ concomitant knee injury aside from meniscus tear and MCL tear not requiring surgery
- ✕ prior surgery to either knee
- ✕ prior injury to either knee requiring crutches
- ✕ history of thromboembolic disease
- ✕ current use of combination hormonal contraception
- ✕ chronic NSAID use
Where it's recruiting
California
Stanford
Source: ClinicalTrials.gov · NCT03552705 · last updated 2026-02-27